Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Conrad Simpfendorfer, entitled “When is the optimal timing for PCI: before or during TAVI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Flavio Ribichini, entitled “TAVI intermediate risk: Reality or passion?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dra. Carla Agatiello, entitled “TAVI: Clinical Evidence of long term durability of prosthetic valves”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Oscar Méndiz, entitled “TAVI: Evidencia para pacientes de riesgo intermedio”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Fabio Sandoli, entitled “When and how to interving patients with CAD undergoing TAVI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Courtesy of Dr. Carlos Fava. Moderate/severe paravalvular regurgitation (PVR) after TAVR is present in 10%-14% of all cases, according to different series. The treatment of choice is post-dilation, generally effective in most cases. However, this strategy carries a risk of stroke. The true impact of this conduct is still unclear. This review analyzed 6 studies that included 5007 patients; 889 of...
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve implantation has already proven to be beneficial for high-risk and inoperable patients. In that sense, it is also an increasingly frequent solid option for lower-risk patients. However, due to the presence of valve calcifications, it may occasionally be necessary to assess the benefits and risks of valve dilation...
Courtesy of SBHCI. The occurrence of a periprocedural neurological events is associated to an increased risk of death and morbidity at long term, both for transcatheter aortic valve replacement (TAVR) and for surgery. The SURTAVI study, recently presented at the ACC meeting and simultaneously published by NEJM, showed that TAVR with self-expandable CoreValve or Evolut...
Courtesy of the SBHCI. There is little data about the use of transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis at low surgical risk. Many of the questions involve long term duration of valves (over 10 years) when treating younger patients with longer life expectancy. The NOTION study aims at comparing...
Silent ischemic embolic lesions are common after transcatheter aortic valve implantation (TAVI). The use of cerebral protection devices might reduce the occurrence of these embolic lesions. Multiple studies with different devices, designs, and outcomes challenge the usefulness of cerebral protection during TAVI. A comprehensive analysis of the literature was necessary to obtain a more...